Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience

Amaris Balitsky, MD, Anca Prica, MD, Jan M.A. Delabie, MD PhD, Michael Crump, MD, Vishal Kukreti, MD FRCPC, John Kuruvilla, MD

Blood (2015) 126 (23): 5057.

https://doi.org/10.1182/blood.V126.23.5057.5057

Published: 2015

Journal Articles

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Sara Farshchi-Zarabi, MD, Gurdeep Parmar, MD, Esther Masih-Khan, PhD, Sophia Farooki, MD FRCPC, Christine Chen, MD FRCPC, Vishal Kukreti, MD FRCPC, Anca Prica, MD FRCPC, Rodger Tiedemann, MBChB, FRCPC, PhD, Suzanne Trudel, MD, Donna Reece

Blood (2015) 126 (23): 3176.

https://doi.org/10.1182/blood.V126.23.3176.3176

Published: 2015

Journal Articles

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, Darrell White, MD, Martin Gyger, MD, Jonahtan Kaufmann, MD, Andrzej Jakubowiak, MD PhD, Engin Gul, BSc, Lisa W Le, MSc, Zhihua Li, Donna Reece, Vishal Kukreti, MD FRCPC, Richard LeBlanc

Blood (2015) 126 (23): 4234.

https://doi.org/10.1182/blood.V126.23.4234.4234

Published: 2015

Journal Articles

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Michael Kennah, MD, Nastaran Noroozi, MD FRCPC, Esther Masih-Khan, PhD, Tony Panzarella, M.Sc., P.Stat., Donna E Reece, MD FRCPC, Suzanne Trudel, MD, Vishal Kukreti, MD FRCPC, Rodger Tiedemann, MBChB, PhD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 2019.

https://doi.org/10.1182/blood.V124.21.2019.2019

Published: 2014

Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD

Blood (2014) 124 (21): 3450.

https://doi.org/10.1182/blood.V124.21.3450.3450

Published: 2014

Journal Articles

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Victor H Jimenez Zepeda, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Norman Franke, MD, Andrew Winter, Sr., RN, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3396.

https://doi.org/10.1182/blood.V122.21.3396.3396

Published: 2013

Journal Articles

Stem Cell Dose and Time To Engraftment Does Not Predict Outcome After Autologous Stem Cell Transplantation For Relapsed Aggressive NHL

Shane A Gangatharan, MBBS, FRACP, FRCPA, John Kuruvilla, MD, Vishal Kukreti, MD, FRCPC, Armand Keating, Manjula Maganti, Melania Pintilie, Michael Crump, MD FRCPC

Blood (2013) 122 (21): 5542.

https://doi.org/10.1182/blood.V122.21.5542.5542

Published: 2013

Journal Articles

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Donna E. Reece, MD, Madeline Phillips, BAS, Christine I. Chen, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5378.

https://doi.org/10.1182/blood.V122.21.5378.5378

Published: 2013

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Donna E. Reece, MD, Madeline Phillips, BAS, Beryl Chung, Christine I. Chen, MD, Esther Masih-Khan, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3231.

https://doi.org/10.1182/blood.V122.21.3231.3231

Published: 2013

Journal Articles

Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma

Craig B. Reeder, MD, Donna E. Reece, MD, Vishal Kukreti, MD, FRCPC, Joseph Mikhael, MD, Christine I. Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Giovani Piza, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Jose F Leis, MD, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Jacy Spong, BS, RN, BSN, Angela Mayo, PA/NP, Keith Stewart, MD

Blood (2013) 122 (21): 3192.

https://doi.org/10.1182/blood.V122.21.3192.3192

Published: 2013

Journal Articles

Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes

Shane A Gangatharan, MBBS, FRACP, FRCPA, John Kuruvilla, MD, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Mary Gospodarowicz, MD, David C. Hodgson, MD, Alex Sun, MD, Richard Tsang, MD, Manjula Maganti, Melania Pintilie, Michael Crump, MD FRCPC

Blood (2013) 122 (21): 4273.

https://doi.org/10.1182/blood.V122.21.4273.4273

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

Journal Articles

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

Haowei (Linda) Sun, MD, Eshetu Atenafu, MSc, Richard Tsang, MD, Vishal Kukreti, MD, FRCPC, Michael Crump, MD, FRCPC, John Kuruvilla, MD, FRCPC

Blood (2011) 118 (21): 3643.

https://doi.org/10.1182/blood.V118.21.3643.3643

Published: 2011

Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood (2011) 118 (21): 813.

https://doi.org/10.1182/blood.V118.21.813.813

Published: 2011

Journal Articles

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4121.

https://doi.org/10.1182/blood.V118.21.4121.4121

Published: 2011

Journal Articles

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Andrew Winter, Sr., RN, Norman Franke, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4111.

https://doi.org/10.1182/blood.V118.21.4111.4111

Published: 2011

Journal Articles

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Lee Mozessohn, MD, Matthew Cheung, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC, Neil L Berinstein, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, John Kuruvilla, MD, FRCPC, Eugenia Piliotis, MD, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4981.

https://doi.org/10.1182/blood.V118.21.4981.4981

Published: 2011

NARROW

Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Stem Cell Dose and Time To Engraftment Does Not Predict Outcome After Autologous Stem Cell Transplantation For Relapsed Aggressive NHL

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Long-Term Survival With Cybord Induction Therapy In Newly Diagnosed Multiple Myeloma

Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only